Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
- PMID: 34571723
- PMCID: PMC8470828
- DOI: 10.3390/biology10090845
Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
Abstract
Endometrial carcinoma is the most frequent cancer of the reproductive female organs. Most endometrial cancers are diagnosed at early stage (75%). Treatment options depend on pathogenetic, histopathologic and clinical characteristic at the diagnosis. To improve patient management in the near future, recent research has focused on new molecular features; evidence has shown that these give a better definition of patient prognosis and can help in tailoring adjuvant treatments by identifying specific subgroups of patients whose tumors may benefit from specific therapeutic approaches. In this review, we will focus on current knowledge of adjuvant treatment of endometrial carcinoma, using a prognostic-risk group stratification based on pathogenetic, clinical and molecular features, and will take a look at the ongoing trials that will further change the therapeutic approach in coming years.
Keywords: endometrial carcinoma; guidelines; molecular markers; treatment.
Conflict of interest statement
V.S. reports grants from Clovis Oncology, grants from TESARO, grants from GSK, grants from Astra Zeneca, grants from MSD, grants from PHARMAMAR, grants from EISAI, grants from ROCHE, outside the submitted work; G.S. reports personal fees from ROCHE, personal fees from Clovis Oncology, personal fees from Astra Zeneca, personal fees from PharmaMar, personal fees from Tesaro, outside the submitted work; D.L. reports grants from ROCHE, grants and personal fees from GSK, grants and personal fees from Clovis Oncology, grants and personal fees from MSD, grants from Incyte, grants and personal fees from PHARMAMAR, grants from IMMUNOGEN, grants and personal fees from GENMAB, personal fees from AMGEN, grants and personal fees from ASTRA ZENECA, outside the submitted work; A.G., E.G., L.M., C.R., C.L., M.T.P. have nothing to disclose. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Similar articles
-
Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.Cancer Treat Rev. 2019 May;75:1-11. doi: 10.1016/j.ctrv.2019.02.002. Epub 2019 Feb 26. Cancer Treat Rev. 2019. PMID: 30849607 Review.
-
Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.Expert Rev Anticancer Ther. 2019 Jan;19(1):51-60. doi: 10.1080/14737140.2019.1531708. Epub 2018 Oct 24. Expert Rev Anticancer Ther. 2019. PMID: 30295094 Review.
-
[Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].Akush Ginekol (Sofiia). 2009;48 Suppl 1:3-11. Akush Ginekol (Sofiia). 2009. PMID: 20387272 Bulgarian.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?Cancers (Basel). 2020 Sep 10;12(9):2577. doi: 10.3390/cancers12092577. Cancers (Basel). 2020. PMID: 32927671 Free PMC article.
Cited by
-
It is time to implement molecular classification in endometrial cancer.Arch Gynecol Obstet. 2024 Mar;309(3):745-753. doi: 10.1007/s00404-023-07128-z. Epub 2023 Jul 6. Arch Gynecol Obstet. 2024. PMID: 37410149 Review.
-
Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.Curr Oncol. 2023 Feb 14;30(2):2277-2289. doi: 10.3390/curroncol30020176. Curr Oncol. 2023. PMID: 36826137 Free PMC article.
-
The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.J Pathol. 2022 Dec;258(4):426-436. doi: 10.1002/path.6012. Epub 2022 Oct 25. J Pathol. 2022. PMID: 36169332 Free PMC article.
-
Endometrial Cancer in Pre-Menopausal Women and Younger: Risk Factors and Outcome.Int J Environ Res Public Health. 2022 Jul 25;19(15):9059. doi: 10.3390/ijerph19159059. Int J Environ Res Public Health. 2022. PMID: 35897440 Free PMC article.
-
The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers.Cancers (Basel). 2022 Apr 8;14(8):1877. doi: 10.3390/cancers14081877. Cancers (Basel). 2022. PMID: 35454785 Free PMC article.
References
-
- Sant M., Chirlaque Lopez M.D., Agresti R., Sánchez Pérez M.J., Holleczek B., Bielska-Lasota M., Dimitrova N., Innos K., Katalinic A., Langseth H., et al. Survival of Women with Cancers of Breast and Genital Organs in Europe 1999–2007: Results of the EUROCARE-5 Study. Eur. J. Cancer. 2015;51:2191–2205. doi: 10.1016/j.ejca.2015.07.022. - DOI - PubMed
-
- Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Comparison of Estrogen and Progesterone Receptor, Ki-67, and P53 Immunoreactivity in Uterine Endometrioid Carcinoma and Endometrioid Carcinoma with Squamous, Mucinous, Secretory, and Ciliated Cell Differentiation. Hum. Pathol. 1998;29:924–931. doi: 10.1016/S0046-8177(98)90197-6. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources